October 29th marks the 41st anniversary of one of biotechnology’s most significant milestones — the approval by the Food and Drug Administration of Humulin, human insulin synthesized in genetically engineered bacteria to treat diabetes. The first “biopharmaceutical,” or drug made with molecular genetic engineering techniques, to be approved, it launched a revolutionary era in drug development.